What is ChipCare?
ChipCare is a point-of-care (POC) diagnostics company focused on delivering lifesaving diagnostic capabilities to underserved populations. The company's flagship product, the ChipCare PAx (Polyvalent Analyzer), is a portable, user-friendly multiplex reader. It utilizes low-cost microfluidic disposable cartridges to achieve lab-quality results in approximately 15 minutes, representing a significant technological advancement developed from research at the University of Toronto.
How much funding has ChipCare raised?
ChipCare has raised a total of $25.8M across 3 funding rounds:
Unspecified
$2M
Series A
$5M
Series B
$18.8M
Unspecified (2013): $2M with participation from Maple Leaf Angels and MaRS Innovation
Series A (2015): $5M led by Maple Leaf Angels, MaRS Innovation, and Epic Capital
Series B (2016): $18.8M supported by Biotech Alliances International
Key Investors in ChipCare
Biotech Alliances International
Biotech Alliances International, Inc. is a Miami-based life science advisory firm that specializes in providing strategic insights to biotechnology, pharmaceutical, and healthcare companies, as well as their investors. The firm offers services in capital raising advisory, mergers and acquisitions, IPO preparation, and board-level strategic counseling.
Maple Leaf Angels
Maple Leaf Angels is Toronto's largest angel investor network, dedicated to supporting Canadian startups. The organization comprises high net worth individuals who invest in seed and early-stage technology companies, providing not only capital but also strategic guidance and mentorship.
MaRS Innovation
MaRS Innovation is a leading provider of commercialization services, early-stage funding, and deal-brokering with industry and private investors. As a member-based organization made up of 14 member institutions, MaRS Innovation's mandate is to drive the commercialization of their most promising research breakthroughs.
What's next for ChipCare?
With a major enterprise-level funding context and a recent strategic investment, ChipCare is poised for significant scaling and market penetration. This capital will likely fuel further development of its diagnostic platform, expansion into new markets, and the establishment of strategic partnerships to broaden access to its technology. The company's trajectory suggests a focus on commercialization and widespread adoption of its innovative POC diagnostic solutions.
See full ChipCare company page
